You are a key healthcare player, who develops and/or markets medicines, vaccines, medical devices or in vitro diagnostics.
You are looking for a provider able to optimize the value of your products to health authorities, in order to maximize their reimbursement.
stève consultants is a consulting expert in Market Access and HEOR. Our qualified consultants, our network and our human approach focusing on deliverables quality and timelines compliance makes stève consultants an key player in France since 2006.
Stève Bénard – Executive Director of stève consultants
Josselin Boussel, Head of Market access
of stève consultants since 2010
For more than 10 years, stève consultants has been specialized in:
- strategic consulting for pricing & reimbursement,
- development of arguments in clinic, public health interest, therapeutic value (SMR: service medical rendu and ASMR: amélioration du service medical rendu) and target population,
- writing of listing and relisting dossier attending for health authorities (transparency dossier, CNEDiMTS and economic).
Our touch: Working closely with you through evaluation by the French National Authority for Health (HAS) as well as through negotiations with the French Economic Committee of Healthcare Products (CEPS).
Our dedicated consultants conceive and develop:
simulation tools to serve the medico-marketing strategy,
health economic evaluation attending for health authorities (efficiency evaluation by the French Economic Committee of Evaluation in Public Health (CEESP), pricing negotiations with the CEPS…).
Design / Adaptation
budget impact mode
epidemiologic and clinic
Our touch: Source of strategical and technical proposals alongside the project.
Aurélie Schmidt, Head of HEOR
of stève consultants since 2006
Charlotte Cancalon, Health-economist statistician
of stève consultants since 2009
stève consultants realizes your observational studies from database notably claim database (PMSI, EGB, SNIIR-AM):
post-inscription studies demanded by health authorities,
ad-hoc pharmacocoepidemiological, epidemiologic or medico-economic study to sustain your Market Access strategy
Our touch: Support of a dedicated scientific steering committee / possible cross with clinical registry or physician’s panel.